You haven't searched anything yet.
Summary
The Quality Control Manager for Biologics is responsible for managing the quality control processes for biologics products, ensuring their integrity and compliance from development to production. This includes managing CDMO activities related to QC aspects of Visterra clinical trial candidates, developing and implementing QC protocols, managing stability programs, and ensuring compliance with regulatory requirements.
This is a full-time position based in Visterra’s facility in Waltham, MA.
Responsibilities
Minimal requirements
Company
Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Our proprietary technology platform enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets. Applying this technology to disease targets that are not adequately addressed by traditional therapeutic approaches, we are developing a robust pipeline of novel therapies for patients with unmet needs.
Visterra is a wholly owned subsidiary of Otsuka America, Inc., which is a U.S. holding company and a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd. of Japan. Visterra has approximately 85 employees and is located in Waltham, Massachusetts.
Visterra provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.
Full Time
$102k-129k (estimate)
07/02/2024
07/19/2024
visterrainc.com
WALTHAM, MA
25 - 50
2008
BRIAN PEREIRA
$5M - $10M
Pharmaceutical
Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Our proprietary technology platform enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets. Applying this technology to disease targets that are not adequately addressed by traditional therapeutic approaches, we are developing a robust pipeline of novel therapies for patients with unmet needs. Our most advanced pro...gram is in Phase 2 clinical development. In addition, Visterra has established a number of partnerships to progress novel antibodies engineered to treat significant diseases with limited treatment options.
More
Show less